Dr. Bazhenova on Prevalence of NTRK Mutations in NSCLC and Emerging Treatments

Lyudmila A. Bazhenova, MD
Published: Thursday, Jul 26, 2018



Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, University of California, San Diego, discusses the prevalence of NTRK mutations in non–small cell lung cancer (NSCLC) and what emerging therapeutic strategies are for these patients.

NTRK mutations are generally rare in solid tumors, with an overall prevalence of 1% to 2%. However, it is more common in head and neck cancer and is also present in sarcomas and thyroid cancer, Bazhenova says. Overall, the mutations are rare but there are drugs in development that are very active. It is imperative that oncologists test all of their patients for NTRK mutations, she adds.

Currently, entrectinib and larotrectinib are the two agents in development that have shown remarkable efficacy and durable responses. Both drugs also demonstrate good tolerability and acceptable safety profiles as well, Bazhenova says. In May 2018, the FDA granted larotrectinib a priority review designation to a new drug application for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with an NTRK gene fusion.

<<< 2018 International Lung Cancer Congress


Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, University of California, San Diego, discusses the prevalence of NTRK mutations in non–small cell lung cancer (NSCLC) and what emerging therapeutic strategies are for these patients.

NTRK mutations are generally rare in solid tumors, with an overall prevalence of 1% to 2%. However, it is more common in head and neck cancer and is also present in sarcomas and thyroid cancer, Bazhenova says. Overall, the mutations are rare but there are drugs in development that are very active. It is imperative that oncologists test all of their patients for NTRK mutations, she adds.

Currently, entrectinib and larotrectinib are the two agents in development that have shown remarkable efficacy and durable responses. Both drugs also demonstrate good tolerability and acceptable safety profiles as well, Bazhenova says. In May 2018, the FDA granted larotrectinib a priority review designation to a new drug application for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with an NTRK gene fusion.

<<< 2018 International Lung Cancer Congress

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x